Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

LLY

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

LLY

AI Research Report

Powered by Claude

Ready to analyze LLY

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

A-
Stonvex Quant Grade
77.5/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
A-
78 / 100

Today's volume vs prior session average.

Volatility
B
62 / 100

Absolute daily price move vs peers.

News Flow
A
84 / 100

24h article count relative to the universe.

Sentiment
A+
97 / 100

AI-classified polarity of recent news.

Dollar Flow
B+
69 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
A-
79 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Biotech →
MRNA
Moderna
$42.80
+5.29%
UNH
UnitedHealth
$485.20
-2.51%
NVO
Novo Nordisk
—
—
BNTX
BioNTech
—
—
REGN
Regeneron
—
—
VRTX
Vertex Pharma
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Eli Lilly and Co

Eli Lilly and Co

Pharmaceuticals·NEW YORK STOCK EXCHANGE, INC.·US·IPO 1970-07-09

Analyst Consensus

Buy
Based on 39 analysts
Period: 2026-04-01
30 Buy (77%)8 Hold (21%)1 Sell (3%)
Rating Distribution
Strong Buy
12
Buy
18
Hold
8
Sell
1
Strong Sell
0
Trend
2026-04
30/8/1
2026-03
30/9/0
2026-02
27/10/0
2026-01
28/9/0
📅 Earnings in 16d (Apr 30)
  • Yahoo·5h ago

    Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company

    ROCKVILLE, Md., April 14, 2026--Linden Lake Labs ("L3"), an early-stage life sciences platform committed to advancing innovative therapies, today announced that its portfolio company, CrossBridge Bio, has entered into a definitive agreement to be acquired by Eli Lilly and Company.

  • Yahoo·5h ago

    Novo Nordisk Taps OpenAI to Accelerate Drug Development

    Partnership aims to boost efficiency as competition in weight-loss drugs intensifies

  • Yahoo·6h ago

    Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform

    Vasa Therapeutics ("Vasa"), a clinical stage biopharmaceutical company developing transformative therapies for cardiovascular, neuromuscular, and age-related disorders, today announced an agreement with Eli Lilly and Company ("Lilly") that enables the company to utilize Lilly TuneLab, an AI-enabled drug discovery platform that provides biotech companies access to drug discovery models trained on Lilly's proprietary data.

  • Yahoo·6h ago

    CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates

    HOUSTON, April 14, 2026--CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs) today announced a definitive agreement to be acquired by Eli Lilly and Company ("Lilly").

  • Yahoo·7h ago

    Novo Nordisk Stock Rises. An OpenAI Partnership Can Help It Find the Next Ozempic.

    Novo Nordisk stock was rising on Tuesday after the Ozempic and Wegovy maker unveiled a partnership with ChatGPT developer OpenAI that it said would speed up drug discovery. Novo’s American depositary receipts climbed 2.9% to $39.09 ahead of the opening bell. The ADRs were rising after Novo announced a strategic partnership with OpenAI.

  • Yahoo·7h ago

    Novo Nordisk and OpenAI forge alliance to drive speedy drug development

    This deal comes as the total value of AI partnerships takes a 120% uptick year-on-year between 2024 and 2025, as per GlobalData.

  • Finnhub·8h ago

    Eli Lilly to Buy Pre-Clinical Biotech CrossBridge for Up to $300 Million

    By Colin Kellaher Eli Lilly has agreed to pay up to $300 million for pre-clinical biotechnology company CrossBridge Bio in a deal that bolsters the drugmaker's cancer pipeline. The purchase...

  • Finnhub·8h ago

    FDA asks Lilly for more liver injury data on newly approved obesity pill

    The U.S. Food and DrugAdministration has asked Eli Lilly for more data onliver injury linked to its newly approved obesity pill,according to a letter posted on the health regulator's website. ...

  • View all news →

Recent insider activity

View all →
  • 4FORM 4
    28d ago
  • 4FORM 4
    28d ago
  • 4FORM 4
    28d ago
  • 4FORM 4
    28d ago
  • 4FORM 4
    Feb 19
NEW YORK STOCK EXCHANGE, INC.Market open
Eli Lilly and Co
Pharmaceuticals
$936.67
$7.12 (+0.77%)
Open
$927.40
Prev close
$929.55
Day range
$918.64 – $939.93
52W range
$623.78 – $1133.95
Mkt cap
$878.26B
P/E
42.8
EPS
$22.96
Beta
0.52

Fundamentals

Valuation
Market Cap
$878.26B
P/E (TTM)
42.83S&P avg ~22
P/S (TTM)
13.56S&P avg ~2.8
P/B
38.29S&P avg ~4.5
P/FCF
116.84S&P avg ~26
EPS (TTM)
$22.96
Book/sh
$28.09
Cash/sh
$7.69
Profitability
Gross Margin
83.04%avg ~45%
Operating Margin
40.35%avg ~15%
Net Margin
31.66%avg ~12%
ROE
97.85%avg ~18%
ROA
19.76%avg ~7%
ROI
33.32%
Payout Ratio
26.09%
FCF/sh
—
Growth & Health
Rev Growth YoY
44.70%
Rev Growth 5Y
21.58%
EPS Growth YoY
95.89%
EPS Growth 5Y
27.59%
Current Ratio
—
Quick Ratio
0.78
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.52
52W High
$1133.95
52W Low
$623.78
Avg Vol (10D)
2.84M
Avg Vol (3M)
3.09M
Div Yield
0.74%
Div/sh (TTM)
—
Analyst
Buy (39)
Price Performance
5D-0.17%
MTD+1.06%
3M-14.34%
6M+10.00%
YTD-13.50%
1Y+28.94%

Factor Grades

View details →
B-
Overall score: 62/100
D-
Valuation
A
Growth
A
Profitability
C-
Momentum
B-
Financial Health